Core Viewpoint - Bon Natural Life Limited has announced a share repurchase program allowing the company to buy back up to $1.0 million of its Class A ordinary shares, indicating confidence in its financial position and commitment to shareholder value [1]. Group 1: Share Repurchase Program - The company is authorized to repurchase shares in the open market, with the timing and number of shares depending on various factors such as price, market conditions, and corporate liquidity requirements [2]. - The share repurchase program is flexible and does not obligate the company to purchase a specific number of shares, allowing for potential suspension, modification, or discontinuation at any time [2]. Group 2: Appointment of Agent - Bon Natural Life Limited has appointed TradeUp Securities as its exclusive agent to facilitate the purchase of securities under the terms of a Purchase Plan Agreement [3]. Group 3: Company Overview - Bon Natural Life Limited is a Cayman Islands company operating in the natural, health, and personal care industries, emphasizing its role as a leading bio-ingredient solution provider [4].

Core Insights - Bon Natural Life Limited (BON) has entered a non-exclusive sales cooperation agreement with Shanghai Risesun International Trade Co., Ltd. for a total contract value of US$ 24 million over 24 months [1] - The agreement focuses on marketing, distributing, and selling BON's tea pigment series health products in China [1] - Tea pigments are gaining traction in the digestive wellness and blood glucose regulation sectors, with potential for a market valuation exceeding $1 billion [2] Company Developments - CEO Hu Yongwei emphasized that the collaboration with Shanghai Risesun will accelerate BON's entry into the high-growth digestive health sector [3] - The partnership is seen as a strategic milestone for BON, enhancing its position in the tea pigment-based product market [3] - The company anticipates that this alliance will drive revenue and earnings growth, benefiting shareholder returns through sustainable market expansion [3]

Core Viewpoint - Bon Natural Life Limited has entered into a 36-month exclusive cooperation agreement with Beijing Huahai Keyuan for the distribution of its patented postbiotic hypoglycemic ingredients, aiming to penetrate the global blood sugar health market with a contract value of 32 million US dollars [1]. Company Summary - Bon Natural Life Limited is a leading provider of bio-ingredient solutions in the natural, health, and personal care industry, focusing on innovative hypoglycemic solutions [1][5]. - The company holds a patent for a postbiotic hypoglycemic ingredient that effectively regulates blood sugar levels, particularly post-meal glucose spikes, and is characterized by its safety and ease of use [2]. Industry Summary - The postprandial blood glucose control market is valued at over 30 billion US dollars and is experiencing a compound annual growth rate of 7.5% [3]. - The company anticipates significant advancements in its hypoglycemic product line over the next 2-3 years, which is expected to drive sales growth and enhance investment value [4].

Core Viewpoint - Bon Natural Life Limited will implement a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement of $1.00, effective May 19, 2025 [3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 25 issued and outstanding Class A ordinary shares into one new Class A ordinary share, with no fractional shares issued [1]. - The new CUSIP number for the Class A ordinary shares post-split will be G14492204, and trading will continue under the existing symbol "BON" [2]. - The authorized share capital will increase to 1,000,000,000 Class A ordinary shares, 50,000,000 Class B ordinary shares, and 50,000,000 preference shares [4]. Group 2: Class Rights and Shareholder Approval - The conversion rate for Class B ordinary shares will change from a 1:1 basis to a 1:25 basis for conversion into Class A ordinary shares [5]. - The reverse stock split and related changes were approved by shareholders during an extraordinary general meeting on April 15, 2025 [6].

Core Viewpoint - BON Natural Life Limited has launched a new sleep health product series utilizing a proprietary delivery system aimed at enhancing the bio-activity of glucoraphanin, a compound found in broccoli, to improve health benefits [1][3][4] Group 1: Product Development - The new product series is developed using the "Glucoraphanin-Myrosinase" delivery system, which is patent-pending and designed to enhance the absorption and utilization of glucoraphanin in the body [1][3] - The delivery system aims to improve the conversion efficiency of glucoraphanin to sulforaphane, addressing challenges related to bio-availability [3][4] Group 2: Health Benefits - Glucoraphanin is linked to various health benefits, including anti-cancer properties, sleep regulation, neuro-protective effects, digestive health support, anti-inflammatory, antioxidant, and anti-aging effects [2] - The enzymatic conversion of glucoraphanin to sulforaphane is typically inefficient, which limits the health benefits derived from broccoli [2] Group 3: Market Potential - The company anticipates that the new sleep health products will achieve market expansion and significantly impact the sleep health market dynamics [4] - The innovative delivery system is expected to combine scientific rigor with commercial potential, addressing unmet needs in sleep health [4]

Core Viewpoint - The Bonduelle Group reported stable sales for Quarter 3 of FY 2024-2025, confirming its annual objectives despite slight declines in overall sales for the first nine months of the fiscal year [3][4][19]. Sales Performance - Sales for Quarter 3 (January 1 - March 31, 2025) were 529.3 million euros, showing a slight increase of 0.3% compared to the previous year [3][6]. - For the first nine months of FY 2024-2025, total sales amounted to 1,648.7 million euros, reflecting a decline of 1.1% on both reported and like-for-like bases [4][6]. Geographical Performance - The Europe Zone, accounting for 60.7% of business activity, experienced a decline of 5.0% in sales on reported figures and 5.2% on a like-for-like basis for the first nine months [9][10]. - The Non-Europe Zone, which represents 39.3% of business activity, saw an increase of 5.7% on reported figures and 6.0% on a like-for-like basis during the same period [11][12]. Segment Performance - Canned products sales decreased by 6.0% for the first nine months, while frozen products saw a slight decline of 0.7%. Fresh processed products, however, grew by 5.9% [8]. - In Quarter 3, canned products sales fell by 4.4%, frozen products by 4.0%, while fresh processed products increased by 8.4% [8]. Strategic Developments - The Bonduelle Group is in the process of selling its packaged salad business in France and has already sold the German segment to Taylor Farm, which represented sales of 60 million euros [15][16][17]. - The planned downsizing of Bonduelle Frais France includes the closure of the Saint-Mihiel plant by February 28, 2025, and a voluntary redundancy plan for the Genas head office [14]. Outlook - Despite challenges such as difficult harvests in Russia impacting profitability, the Bonduelle Group aims to stabilize sales and maintain recurring operating income for the fiscal year [19].

Core Points - Bon Natural Life Limited has received notification from Nasdaq regarding non-compliance with the Minimum Bid Price Requirement due to its Class A ordinary shares closing bid price being below $1.00 for 30 consecutive business days [1] - The company's securities have also closed at $0.10 or less for the last ten consecutive trading days, leading to additional grounds for potential delisting [1] - An additional Notification Letter indicated that Nasdaq has determined to delist the company's securities based on public interest concerns related to its March 2025 best efforts offering [2] - The company has filed an appeal and requested a hearing before a Nasdaq Listing Qualifications Panel, which will stay the delisting pending the Panel's decision [3] - The company is evaluating options to regain compliance with Nasdaq Listing Rules, but there are no guarantees of success in this process [3] Company Overview - Bon Natural Life Limited is a Cayman Islands company engaged in the natural, health, and personal care industries [4]

Core Insights - Bon Natural Life Limited has entered a 24-month supply agreement worth $12 million with Shanghai Yunsheng to co-develop apple polyphenol-infused health solutions, utilizing BON's patented extraction technology [1] - The incorporation of apple polyphenols into protein supplements is expected to provide clinically validated benefits such as lipid management and improved body composition [2] - Comparable apple polyphenol blends have achieved significant market success, selling over 500,000 units monthly and generating $40 million in recurring revenue, indicating strong consumer demand for nutraceutical products [3] - The company aims to leverage its vertically integrated supply chain to dominate the apple polyphenol market, anticipating revenue growth from both standalone nutraceuticals and functional food additives while maintaining margin control [4]

XI’AN, China, April 08, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced our biotech innovation addresses nutritional critical challenges through a patent-pending Glucoraphanin-Myrosinase co-delivery system that significantly enhances the bio-activity of glucoraph anin, a key bio-active compound in broccoli. Broccoli stands as a nutrient-rich super food containing ...

Core Insights - Bon Natural Life Limited has developed a patent-pending Glucoraphanin-Myrosinase co-delivery system that enhances the bio-activity of glucoraphanin, a key compound in broccoli [1][3] - Sulforaphane, derived from glucoraphanin, is linked to various health benefits including anti-cancer properties, neuroprotection, and digestive health [2][3] - The new technology aims to improve the conversion efficiency of glucoraphanin to sulforaphane, addressing the bio-availability issue and unlocking significant market potential in functional foods and beverages [3][4] Company Overview - Bon Natural Life Limited operates in the natural, health, and personal care industries, focusing on bio-ingredient solutions [1][4] - The company is scheduled to enter the market with its new technology in Q2 2025, which is expected to broaden the broccoli-derived wellness market [4] Market Potential - The advancements in sulforaphane applications are projected to create a multi-billion-dollar market opportunity across various sectors, particularly in anti-tumor therapies and mental health support [3]